Dr. Schuehsler serves as Chairman and CEO of TVM Capital Healthcare in Dubai and Singapore. TVM Capital Healthcare is a private equity investment platform created in 2009 focused on investing in and building transformational healthcare companies in the fast-growing emerging economies of the Middle East and Southeast Asia, including the expansion of Western companies into these regions.

 

Most recently TVM Capital Healthcare announced the first closing of its new Southeast Asia Fund, following the oversubscribed closing of its growth capital fund with a focus on Saudi Arabian healthcare transformation at USD 254M in late 2024. With this fund, the firm intends to mobilize total capital for investment in Saudi growth companies of more than USD 500M for about 10 portfolio companies in sub-sectors such as medical product manufacturing and single specialty clinics in fields such as post-acute and chronic care, home health and disease management, reproductive medicine, oncology, cardiology and the rapidly growing field of digital health solutions.

 

Dr. Schuehsler served as chairman or director of several healthcare growth companies since 2010, both in the field of specialized clinics as well as medical device manufacturing and longevity medicine. He also holds a director position of cancer therapy company, invIOs Holding AG, in Vienna, Austria.

 

Dr. Schuehsler joined the original TVM Capital company (Techno Venture Management GmbH) in 1990 in Munich. From the beginning, he led the firm’s life science practice and later as Managing Partner he steered the firm through several transitions of ownership and strategy. He raised close to USD 1.2bn, was the deal maker on more than 30 direct investments in life science companies in Europe and the U.S., oversaw more than 100 investments in the health industry by teams out of Munich and Boston and had more than 50 IPOs and 30 M&A exit transactions in the portfolio. His tenure with TVM Capital ended in 2012. During his tenure as Managing Partner, he developed TVM Capital into the leading and largest life science investor in Germany in the 1990s, one of the leading European firms in the sector and one of the most active U.S. East Coast life science investors in the 2000’s. 

 

Starting in 2007, he spearheaded the expansion of TVM Capital into the field of emerging market healthcare private equity which was eventually domiciled in Dubai in 2009 and expanded to Singapore in late 2020. In 2010, he and co-founder, Hoda Abou-Jamra, bought out the German company and partners and established TVM Capital Healthcare as a fully independent entity. 

 

In terms of industry representation, from 2003 to 2007, Dr. Schuehsler served as chairman of the Professional Standards Committee of the European Private Equity and Venture Capital Association (EVCA, now “Invest Europe”), where he led a team of up to 10 finance, audit and legal specialists as well as industry practitioners in the development and  improvement of PE/VC industry guidance documents, such as the EVCA Code of Conduct. In 2007, he was elected chairman of EVCA for the usual one-year term Dr. Schuehsler also was as a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany. In 2014-2017, he served on the Steering Committee of the MENA Private Equity Association.

 

Dr. Schuehsler also was a member of the Technology Advisory Committee to chancellor Helmut Kohl in Germany, was a board member of Max-Planck Innovation GmbH in Munich for more than 10 years and for several years was a member of the Selection Committee for the Technology Pioneers program of the World Economic Forum (WEF).

Hoda Abou-Jamra is the Co-Founder and Managing Partner of TVM Capital Healthcare and is currently based in Singapore. She played a pivotal role in establishing the firm’s presence in the Middle East in 2007, leading the launch of one of the first healthcare-focused private equity investment platforms in the MENA region. Recognizing similar structural needs and opportunities in Asia, Hoda later expanded the business to Singapore to advance access to high-quality, affordable specialty healthcare in Southeast Asia, culminating in the first close of the TVM Healthcare Southeast Asia Fund in 2025.

In 2025, Hoda was named one of the “Top 15 Women Leaders in the Middle East” by the Women Leaders Summit KSA. Her experience building cross-border healthcare platforms across the U.S., Europe, the Middle East, and Southeast Asia has shaped TVM Capital Healthcare into a successful emerging markets investor with a dual mandate: strong commercial value creation and measurable social impact with top quartile financial track record.

Hoda has been instrumental in using her global networks to build bridges between healthcare ecosystems in the U.S. and Europe and fast-growing markets across the Middle East and Southeast Asia, enabling the transfer of know-how, technology, and operating models to improve patient outcomes at scale.

Hoda currently serves on the boards of Manzil Healthcare Services (UAE) and Amecath Medical Technologies, a medical devices company. She is also the Chairperson of Alina Vision, an ophthalmology platform based in Vietnam, and a Board Member of 2X Global, where she leads TVM Capital Healthcare’s commitment to the 2X Challenge, advancing gender-smart investing and women’s economic participation.

She is an active contributor to global networks focused on women’s leadership and healthcare innovation, including 100 Women in Finance, PEWIN, WBL – Women Leading in Healthcare, the Dubai Business Women Council, and PhiSB. She also co-founded and served as the founding Chair of the 30% Club MENA, advocating for gender diversity in corporate governance.

Hoda has been appointed to the International Advisory Council of Mass General Brigham (Boston), one of the leading academic medical systems in the United States. She holds a degree from Northeastern University’s Bouvé College of Health Sciences, School of Pharmacy

Tristan de Boysson joined the firm as Managing Partner in H2 2020, adding more than 20 years of experience in Private Equity gained as CEO of Amanat Holdings PJSC, the largest integrated healthcare and education investment company in the MENA region listed on the Dubai Financial Market, and, from 1998 to 2018, as Managing Director at Investcorp, a leading global manager of alternative investments.

 

He joined Investcorp initially as a member of the European Private Equity team based in London where he led, executed, managed and realized private equity transactions across Europe and then transferred to Bahrain in 2008 where he launched Investcorp’s first Middle East focused fund and, as Co-Head of Investcorp Private Equity MENA, deployed over $1.5 billion of capital in 16 majority and minority private equity transactions in the MENA region and in Turkey, in the Healthcare, Consumer & Retail, Industrial and Technology sectors.

 

Tristan worked previously at McKinsey & Company’s Paris office where, as an Associate Principal, he advised clients on strategy/valuation, organizational and operational improvement issues. He holds a Master’s degree in Economics from ESSEC – Paris and an MBA from INSEAD.

Orhan Osmansoy has over 20 years of experience in the fields of private equity, merchant banking, and equity capital markets at leading financial services firms. Prior to his current role he was a Managing Director at Frontier Management Group, where he worked with the broader team at Apollo Global Management to source and evaluate private equity and private credit transactions and present investment ideas across a wide range of transaction types including leveraged buyouts, mezzanine financings, and structured purchases.

 

Prior to joining Frontier, Orhan held Board-level and senior responsibility for NAC Ventures SPC, a Kuwaiti creditor-owned restructuring SPV. He had oversight of NAC’s USD 700 million portfolio, with responsibility for the restructuring and monetization of assets including direct investments, listed equities, real estate, and private fund holdings.

 

Previously, he was Chief Executive Officer of The National Investor (TNI), an Abu Dhabi-based merchant banking institution. As CEO of TNI, he positioned the firm among the leading investment management and advisory companies in the GCC and focused the institution on four key areas comprising private equity, investment banking, asset management, and principal investing. Orhan was a Managing Director at Dexter Capital Group, a London-based investment firm that specializes in strategic block investments in Europe where he was responsible for the origination and execution of activist and special situations investments. Earlier in his career, Orhan was a Senior Investment Associate at J.H. Whitney, a US private equity firm where he focused on late-stage venture capital investments and leveraged buyouts in Europe.

 

Orhan began his career at Morgan Stanley where he was a member of both the equity derivatives and corporate finance groups in New York and London.  In this capacity he structured and placed a number of equity-linked derivative products and worked on various financial buyer transactions including reverse LBOs/IPOs, public and private placements of equity securities and high yield debt offerings. Orhan is a graduate of the Wharton School of the University of Pennsylvania (MBA) and the University of Virginia (BS).

40 years of experience in private equity, corporate finance and management consulting​

 Founder and Managing Director of Titan Capital; Former Chairman of the Board of Pacific Internet​

Co-founding Partner and former Managing Director of TPG Capital Asia; built from USD 100 million to USD 6 billion dollars of capital under management​

Founder and Principal of the Asian arms of A.T. Kearney and Booz Allen Hamilton; Former CEO of Ometraco Corporation​

MBA, MS, Columbia University; BS (Hons), Engineering, Birmingham University​

Ghida Harfouche has over 19 years of experience across the investment, pharmaceutical and healthcare sectors, coupled with a strong consulting expertise.

Her responsibilities include sourcing, evaluating and executing on new investment opportunities, performing financial and operational due diligence, fund reporting, as well as being actively involved in fundraising activities. She also actively participates in portfolio management, including the strategic expansion planning for portfolio and affiliated companies as well as developing exit strategies and working on exit readiness.

In a previous tenure, Ghida was a Senior Strategy Consultant at Stem-Pharma. Her role encompassed formulating effective market entry strategies, conducting feasibility and M&A analyses, leading the client relationship across Europe, and providing investment advisory services to a variety of regional and European clients.

In addition to her experience in life science consulting, Ghida has a rich scientific research background focused on pioneering novel target identification. She worked in R&D and clinical research at ‘Institut National de la Santé et de la Recherche Médicale’ (INSERM) and ‘Commissariat à l’Energie Atomique’ (CEA) in France. She received several awards during international scientific conferences. Her research findings have been published in a number of international peer-reviewed journals and she has developed a patent in oncology and photo-protection.

Ghida earned a distinguished PhD in Pharmacology, Cell and Molecular Biology from the University of Paris-Sud XI, France. Complementing her scientific acumen, she holds an MBA from Ecole Supérieure des Affaires, Lebanon, and a DESM (Diplôme d’Etudes Supérieures en Management) from ESCP-Europe, France.

Jannie Tsuei is a Partner in the Singapore office with a decade of transaction experience in Southeast Asia.  Prior to joining us, she led Southeast Asia healthcare investment banking at Morgan Stanley, where she drove healthcare coverage, origination, and execution efforts in the region.  She also served as Chief Operating Officer of the Southeast Asia investment banking at Morgan Stanley from 2018 to 2020. Jannie has been integrally involved in c. US$70Bn of strategic and capital transactions across North America, Asia-Pacific, and Europe.

 

Previously, Jannie worked at Sears Holdings Corporation in a general management rotational program. 

 

Jannie holds an A.B. in literature (magna cum laude) from Harvard College and holds an MBA in Finance (cum laude) from The Wharton School, the University of Pennsylvania.

Damon Jeon is a Senior Associate on TVM Capital Healthcare’s SEA investment team, based in Singapore. Prior to joining TVM Capital Healthcare, he worked as a private equity investment professional covering buyouts, growth equity, and special situations across APAC. He began his career at EY-Parthenon as a strategy consultant specializing in commercial due diligence. Damon holds a BA in Philosophy, Politics, and Economics from the University of Oxford and an MBA from INSEAD.

Tarek Mezher is a Senior Associate on TVM Capital Healthcare’s MENA investment team, based in Dubai. He brings broad experience across the investment and banking sectors. His responsibilities include sourcing investment opportunities and liaising with management teams, as well as managing the assessment, analysis, and due diligence of transactions.

Prior to joining TVM, he worked at the European Bank for Reconstruction and Development (EBRD) in London within the Portfolio Management team, focusing on energy‑related financing and equity investments. He also served in the corporate finance division at Bank Audi in Lebanon, where he structured and syndicated financing solutions across the real estate, construction, and energy sectors in the MENA region.

Tarek holds an MBA from HEC Paris and a Master’s degree in Civil Engineering from Université Saint‑Joseph (USJ), Lebanon.

Elias El Tawil is a Senior Analyst in TVM Capital Healthcare’s investment team, based in Riyadh. He focuses on investment analysis and evaluation alongside deal execution, where he contributes to commercial, operational, legal, and regulatory due diligence efforts.

Prior to TVM, Elias was a Private Equity Analyst at Arqaam Capital, focusing on tech-enabled businesses and special situations across the GCC, MENA and other emerging markets, including Southeast Asia.

He began his career at UK-based Lundy Investors as an Equity Research Analyst covering Saudi petrochemicals and later, supported the launch of the firm’s first private equity fund dedicated to emerging markets.

Elias holds two master’s degrees: a Master’s in Finance from the American University of Beirut, and an MSc in International Finance, with a specialization in Financial Markets & Risk Management, from NEOMA Business School. He is fluent in English, French, and Arabic, and conversational in Italian.